- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Neurothera Labs Inc: Neurothera Labs continues into Ontario | 1 | Stockwatch | ||
| Do | Neurothera Labs Inc.: Neurothera Labs Announces Continuance into Ontario | 1 | TheNewswire | ||
| 24.04. | Neurothera Labs Inc: Neurothera hires bullVestor for IR services | 1 | Stockwatch | ||
| NEUROTHERA LABS Aktie jetzt für 0€ handeln | |||||
| 24.04. | Neurothera Labs Inc.: Neurothera Labs Engages bullVestor for Investor Relations Activities | 2 | TheNewswire | ||
| 16.03. | Neurothera Labs Inc: Neurothera partner Clearmind files patent application | 1 | Stockwatch | ||
| 16.03. | SciSparc Ltd: SciSparc: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy | 1 | GlobeNewswire (USA) | ||
| 16.03. | Neurothera Labs Inc.: NeuroThera Labs- Clearmind Medicine Collaboration Leads to Patent Application for Depression Therapy | 2 | TheNewswire | ||
| 12.03. | SciSparc Ltd: SciSparc: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease | 1 | GlobeNewswire (USA) | ||
| 11.03. | Neurothera Labs Inc: Neurothera Labs publishes int'l patent application | 1 | Stockwatch | ||
| 11.03. | Neurothera Labs Inc.: NeuroThera Labs Announces Publication of International Patent in Collaboration with Clearmind Medicine for Novel Therapy Targeting Weight Loss and Fatty Liver Disease | 3 | TheNewswire | ||
| 10.03. | Neurothera Labs Inc: Neurothera to acquire 54.01% interest in CliniQuantum | 2 | Stockwatch | ||
| 10.03. | SciSparc Ltd: SciSparc: Subsidiary NeuroThera Labs (75%) Signs Definitive Agreement to Acquire Majority Stake in CliniQuantum, Innovator in Quantum-based Clinical trails | 243 | GlobeNewswire (Europe) | TEL AVIV, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), today announced that NeuroThera Labs Inc. (TSXV: NTLX) ("NeuroThera"), a clinical-stage... ► Artikel lesen | |
| 10.03. | Neurothera Labs Inc. Announces Definitive Agreement To Acquire Majority Stake In Cliniquantum Ltd. | 2 | TheNewswire | ||
| 26.02. | XFRA NEW INSTRUMENTS AVAILABLE ON 26.02.2026 | 501 | Xetra Newsboard | The following instruments on XETRA do have their first trading 26.02.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 26.02.2026
Aktien
1 HK0229001182 Raymond Industrial Ltd.
2... ► Artikel lesen | |
| 02.02. | Neurothera Labs Inc: Neurothera Labs wins U.S. patent for AMR tech | 1 | Stockwatch | ||
| 02.02. | Neurothera Labs Inc.: Neurothera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA | 1 | TheNewswire | ||
| 02.02. | SciSparc Ltd: SciSparc: NeuroThera Labs Granted U.S. Patent for Cannabinoid Technology to Overcome Antimicrobial Resistance such as MRSA | 1 | GlobeNewswire (USA) | ||
| 09.01. | Neurothera Labs Inc.: Neurothera Labs Announces Results of AGM | 1 | TheNewswire | ||
| 30.12.25 | Neurothera Labs Inc: Neurothera receives patent from Israel Patent Office | 1 | Stockwatch | ||
| 30.12.25 | Neurothera Labs Inc.: Neurothera Labs Granted Patent by Israeli Patent Office for its Proprietary Opioid-Based Patent Family to Enhance Pain Relief and Reduce Side Effects | 1 | TheNewswire |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 28,910 | +19,86 % | Eton Pharmaceuticals relaunches HEMANGEOL (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution | HEMANGEOL is now available exclusively through Anovo Specialty Pharmacy to streamline access and therapy initiationEton has integrated full Eton Cares patient support, including $0 co-pay for eligible... ► Artikel lesen | |
| BRIGHT MINDS BIOSCIENCES | 86,91 | -1,18 % | Bright Minds Biosciences Announces Closing of US$175 Million Public Offering | NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) ("Bright Minds" or the "Company") today closed its recently announced public offering of 1,945... ► Artikel lesen | |
| LB PHARMACEUTICALS | 31,355 | -1,12 % | This LB Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | ||
| BIOHAVEN | 9,630 | +0,57 % | Biohaven Ltd.: Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results | Prioritizing three key, late-stage clinical programs including Molecular Degrader of Extracellular Proteins (MoDETM) and Targeted Removal of Aberrant Protein (TRAPTM)... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,390 | -1,83 % | KAZIA THERAPEUTICS LTD - 6-K, Report of foreign issuer | ||
| AQUESTIVE THERAPEUTICS | 4,190 | +2,07 % | Vergessene Biotech-Chance: Kann Aquestive Therapeutics vor dem Durchbruch stehen? | Aquestive Therapeutics steht trotz operativer Fortschritte und potenziell wertvoller Pipeline unter massivem Bewertungsdruck. Die Aktie notiert deutlich unter früheren Kursniveaus, während sich fundamentale... ► Artikel lesen | |
| GRACE THERAPEUTICS | 2,340 | +4,46 % | Weekly Buzz: Sanofi, Regeneron Pharmaceuticals Get FDA Nod; It's A No For AbbVie, Grace Therapeutics; Eli Lilly Acquires Kelonia | NEW BRUNSWICK (dpa-AFX) - This week's biotech landscape witnessed regulatory approvals across the U.S. and Europe, alongside FDA rejections, acquisitions, and positive data readouts spanning... ► Artikel lesen | |
| SHUTTLE PHARMACEUTICALS | 0,708 | -31,93 % | Shuttle Pharmaceuticals Holdings Inc.: United Dogecoin Goes Public in Landmark Merger, Powering a Scaled, Next Generation DOGE Mining Operation | Gaithersburg, Maryland--(Newsfile Corp. - May 1, 2026) - Shuttle Pharmaceutical Holdings, Inc. (NASDAQ: SHPH) ("Shuttle") has entered into a definitive merger agreement to acquire United Dogecoin... ► Artikel lesen | |
| OMNIAB | 1,400 | +0,72 % | OmniAb (OABI) Well-Positioned for Momentum Build-Up in 2026 | ||
| MILESTONE PHARMACEUTICALS | 1,870 | +3,89 % | Milestone Pharmaceuticals Inc.: Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST (etripamil) Nasal Spray for the Treatment of PSVT | FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic... ► Artikel lesen | |
| JOURNEY MEDICAL | 5,185 | +0,68 % | Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights | Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi generated net revenues of $14.7 million during the full-year period after its launch in early April 2025 Approximately... ► Artikel lesen | |
| DARE BIOSCIENCE | 2,350 | +3,07 % | Daré Bioscience, Inc.: Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update | Company Highlights Commercial Launch of DARE to PLAY Sildenafil Cream, Pipeline of Women's Health Solutions, and Multiple Near-Term Potential Catalysts Conference Call and Webcast Today at 4:30... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 13,110 | +3,80 % | Generate Biomedicines Prices IPO At $16/shr | WASHINGTON (dpa-AFX) - Generate Biomedicines, Inc. (GENB) on Thursday priced its initial public offering of 25,000,000 shares of stock at $16 per share, raising gross proceeds of $400 million.The... ► Artikel lesen | |
| INHIBIKASE THERAPEUTICS | 1,905 | +0,79 % | Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity | WILMINGTON, Del., March 26, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) ("Inhibikase" or "Company"), a clinical-stage pharmaceutical company developing therapeutics to modify... ► Artikel lesen | |
| ATRIUM THERAPEUTICS | 13,400 | +4,93 % | Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration | SAN DIEGO, April 23, 2026 /PRNewswire/ -- Atrium Therapeutics, Inc. (Nasdaq: RNA) (the "Company"), a biopharmaceutical company dedicated to delivering RNA therapeutics... ► Artikel lesen |
NEUROTHERA LABS INC gehört der Branche Pharma an. Die relative Kursveränderung beträgt aktuell +0,37 % bei einem Aktienkurs von 0,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEUROTHERA LABS INC finden Sie auf Wallstreet Online.